Literature DB >> 1309365

Improved detection of hepatitis C virus antibodies in high-risk populations.

J G McHutchison1, J L Person, S Govindarajan, B Valinluck, T Gore, S R Lee, M Nelles, A Polito, D Chien, R DiNello.   

Abstract

Sera from 483 patients at high (group 1, n = 313) and lower (group 2, n = 170) risk for exposure to hepatitis C were tested for antibodies to hepatitis C using first-generation (c100-3) and second-generation enzyme-linked immunosorbent assays and four-antigen recombinant immunoblot assay. The second-generation enzyme-linked immunosorbent assay and nitrocellulose-based immunoblot assay differ from c100-3-based systems in the addition of expression products from the NS3/NS4 (c33c, c200) and putative nucleocapsid (c22-3) region of the hepatitis C genome. In group 1, the sensitivity of detection of hepatitis C antibodies was 45%, 55% and 46% by the first- and second-generation enzyme-linked immunosorbent assays and recombinant immunoblot assay, respectively. In group 2, antibodies were detected by each test system in 26%, 32% and 7% of patients, respectively. Most sera (99%) reactive with the first-generation enzyme-linked immunosorbent assay were reactive with the second-generation enzyme-linked immunosorbent assay (in group 1, 89% of these specimens demonstrated reactivity to at least one antigen with the immunoblot assay, compared with only 31% in group 2). An additional 12% (group 1) and 6% (group 2) of specimens demonstrated reactivity with the second-generation enzyme-linked immunosorbent assay only (of these, 75% [group 1] and 9% [group 2] demonstrated reactivity to at least one antigen with the immunoblot assay). Ninety-eight percent of specimens not reactive with both enzyme-linked immunosorbent assay test systems were also nonreactive by recombinant immunoblot assay.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309365     DOI: 10.1002/hep.1840150105

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection.

Authors:  S Anderson; C L Nevins; L K Green; H El-Zimaity; B S Anand
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection.

Authors:  D Y Chien; P Arcangel; A Medina-Selby; D Coit; M Baumeister; S Nguyen; C George-Nascimento; A Gyenes; G Kuo; P Valenzuela
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 4.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

5.  Definition of false-positive reactions in screening for hepatitis C virus antibodies.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 6.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

7.  Evaluation of a membrane filter assay system, Ortho HCV Ab Quick Pack, for detection of anti-hepatitis C virus antibody.

Authors:  T Kodama; S Ichiyama; K Sato; T Nada; N Nakashima
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

8.  Hepatitis C markers in hemodialysis patients.

Authors:  C S Huang; M S Ho; C S Yang; C L Lee; C A Tan
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

9.  Study on reliability of commercially available hepatitis C virus antibody tests.

Authors:  H H Feucht; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

Review 10.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.